COVID-19 in a patient receiving adjuvant breast cancer chemotherapy with granulocyte olony-stimulating factor (G-CSF) support: A case report.
COVID-19
breast cancer
chemotherapy
granulocyte-colony stimulating factor
respiratory syndrome
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
28
09
2020
accepted:
19
01
2021
entrez:
27
4
2021
pubmed:
28
4
2021
medline:
28
4
2021
Statut:
ppublish
Résumé
Patients receiving chemotherapy are at high risk for severe infections and complications such as acute respiratory syndrome. The most commonly used adjuvant chemotherapy protocols (docetaxel-cyclophosphamide every 3 weeks or the dose-dense regimen, doxorubicin-cyclophosphamide every 2 weeks followed by paclitaxel) incorporate granulocyte-colony stimulating factor (G-CSF). G-CSF is routinely administered to prevent chemotherapy-associated neutropenia but often results in significant neutrophilia. The present case describes a patient with breast cancer who was successfully treated for severe COVID-19 respiratory syndrome while under adjuvant chemotherapy (docetaxel-cyclophosphamide) treatment and long-term G-CSF support. In addition, the potential effect of G-CSF on the respiratory deterioration of the patient given its cardinal role in innate inflammation and, accordingly, the cytokine storm associated with COVID-19 was described. The case described in the present study indicated how solutions to the immunity challenges faced when treating a patient with chemotherapy may be the source of a larger problem within the coronavirus COVID-19 pandemic.
Identifiants
pubmed: 33903823
doi: 10.3892/mco.2021.2279
pii: MCO-0-0-02279
pmc: PMC8060854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
117Informations de copyright
Copyright: © Yerushalmi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Lancet. 2019 Apr 6;393(10179):1440-1452
pubmed: 30739743
J Clin Oncol. 2003 Apr 15;21(8):1431-9
pubmed: 12668651
Lancet Rheumatol. 2020 Aug;2(8):e448-e449
pubmed: 33521666
Trends Immunol. 2013 Feb;34(2):81-9
pubmed: 23000011
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312863
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Front Oncol. 2020 Apr 23;10:734
pubmed: 32391283
Nat Rev Immunol. 2020 Aug;20(8):507-514
pubmed: 32576980
Lancet Rheumatol. 2020 Aug;2(8):e465-e473
pubmed: 32835256
Blood. 2008 Dec 15;112(13):5193-201
pubmed: 18824600
Am J Hematol. 2020 Aug;95(8):E210-E213
pubmed: 32419212
Nat Rev Dis Primers. 2019 Mar 7;5(1):16
pubmed: 30846703
J Clin Oncol. 2006 Dec 1;24(34):5381-7
pubmed: 17135639
Lancet Respir Med. 2020 Aug;8(8):822-830
pubmed: 32559419
Immunity. 2019 May 21;50(5):1289-1304.e6
pubmed: 31079916
J Exp Med. 2013 Sep 23;210(10):1977-92
pubmed: 24043763
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994